93245-98-8

Usage

Uses

Used in Organic Synthesis:
1,4-Dioxa-spiro[4.5]decane-8-carbaldehyde is used as a key building block in organic synthesis for the preparation of various heterocyclic compounds. Its unique structure and reactivity allow for the creation of complex molecules with diverse applications.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1,4-Dioxa-spiro[4.5]decane-8-carbaldehyde is utilized as a starting material or intermediate in the synthesis of novel drug candidates. Its unique structure and reactivity contribute to the development of innovative therapeutic agents with potential applications in various medical fields.
Used in Agrochemical Industry:
1,4-Dioxa-spiro[4.5]decane-8-carbaldehyde also finds use in the agrochemical industry, where it serves as a building block for the synthesis of new agrochemicals. Its unique properties enable the development of effective compounds for crop protection and other agricultural applications.
Used in Perfume Industry:
In the perfume industry, 1,4-Dioxa-spiro[4.5]decane-8-carbaldehyde may be employed as a fragrance ingredient. Its distinct chemical structure can contribute to the creation of unique and captivating scents, enhancing the sensory experience of perfumes and other fragranced products.

Upstream product

• 51656-90-7 8-methylene-1,4-dioxaspiro[4.5]decane 
• 72445-21-7 1,4-dioxaspiro-<4,5>dec-7-ene-8-methanol 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 107-21-1 ethylene glycol 
• 4746-97-8 cyclohexanedione monoethylene ketal 
• 19493-09-5 Methylenetriphenylphosphorane 
• 26845-47-6 methyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 
• 63579-89-5 triethyl pentane-1,3,5-tricarboxylate 
• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 
• 79-37-8 oxalyl dichloride 
• 67-68-5 dimethyl sulfoxide 
• 3685-22-1 4-hydroxycyclohexanecarboxylic acid 
• 50-00-0 formaldehyd 
• 1489-97-0 ethyl 1,4-dioxaspiro[4.5]decane-8-carboxylate 

Downstream Products

• 1352934-83-8 methyl 1-(4-oxocyclohexyl)propylcarbamate 
• 1352931-47-5 N-(1-((1s,4s)-4-(cyclopropyl(hydroxy)methyl)1-deuterocyclohexyl)azetidin-3-yl)-2-((6-(trifluoromethyl)quinazolin-4-yl)amino)acetamide 
• 1352933-55-1 1-(4,4-dimethoxycyclohexyl)but-3-en-1-amine hydrochloride 
• 1352933-56-2 N-(1-(4,4-dimethoxycyclohexyl)but-3-en-1-yl)acrylamide 
• 1352933-57-3 6-(4,4-dimethoxycyclohexyl)-5,6-dihydropyridin-2 (1H)-one 
• 1187964-14-2 ethyl 3-{1,4-dioxaspiro[4.5]decan-8-yl}propanoate 
• 58012-66-1 3-(4-oxocyclohexyl)propionic acid ethyl ester 
• 23521-81-5 (1,4-dioxaspiro[4.5]dec-8-yl)methanol 

Relevant academic research and scientific papers

DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INIDBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE

Disclosed herein are novel bifunctional compounds formed by conjugating BTK inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.

LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT

PROBLEM TO BE SOLVED: To improve Δn of a liquid crystal compound. SOLUTION: One aspect of the present invention is a liquid crystal compound represented by general formula (i) [where Ri1 is a C1 to 15 alkyl group or the like, Ri2 is

Bcl-2 INHIBITORS

Disclosed herein is a compound of Formula (I) for inhibiting Bcl-2 and treating disease associated with undesirable bcl-2 activity (Bcl-2 related diseases), a method of using the compounds disclosed herein for treating dysregulated apoptotic diseases including cancers and treating autoimmune disease, and a pharmaceutical composition comprising the same.

Photochemical Homologation for the Preparation of Aliphatic Aldehydes in Flow

Cheap and readily available aqueous formaldehyde was used as a formylating reagent in a homologation reaction with nonstabilized diazo compounds, enabled by UV photolysis of bench-stable oxadiazolines in a flow photoreactor. Various aliphatic aldehydes were synthesized along with the corresponding derivatized alcohols and benzimidazoles. No transition-metal catalyst or additive was required to affect the reaction, which proceeded at room temperature in 80 min.

PYRIDINE-1-OXIDE DERIVATIVES AND THEIR USE AS FACTOR XIA INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Development of Fluorinated Analogues of Perhexiline with Improved Pharmacokinetic Properties and Retained Efficacy

We designed and synthesized perhexiline analogues that have the same therapeutic profile as the parent cardiovascular drug but lacking its metabolic liability associated with CYP2D6 metabolism. Cycloalkyl perhexiline analogues 6a-j were found to be unsuitable for further development, as they retained a pharmacokinetic profile very similar to that shown by the parent compound. Multistep synthesis of perhexiline analogues incorporating fluorine atoms onto the cyclohexyl ring(s) provided a range of different fluoroperhexiline analogues. Of these, analogues 50 (4,4-gem-difluoro) and 62 (4,4,4′,4′-tetrafluoro) were highly stable and showed greatly reduced susceptibility to CYP2D6-mediated metabolism. In vitro efficacy studies demonstrated that a number of derivatives retained acceptable potency against CPT-1. Having the best balance of properties, 50 was selected for further evaluation. Like perhexiline, it was shown to be selectively concentrated in the myocardium and, using the Langendorff model, to be effective in improving both cardiac contractility and relaxation when challenged with high fat buffer.

FLUORO-PERHEXILINE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain fluoro-perhexiline compounds of the following formula (also referred to herein as FPER compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, for example, those which are known to be treated with, or known to be treatable with, perhexiline, including, for example, disorders that are ameliorated by the inhibition of carnitine palmitoyltransferase (CPT); cardiovascular disorders such as: angina pectoris; heart failure (HF); ischaemic heart disease (IHD); cardiomyopathy; cardiac dysrhythmia; stenosis of a heart valve; hypertrophic cardiomyopathy (HCM); coronary heart disease; and other disorders, for example, diabetes and cancer. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

BICYCLIC HETEROARYL DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

Bicyclic heteroaryl derivatives of Formula 1, and pharmaceutically acceptable salts, isomers, hydrates and solvates thereof can selectively and effectively inhibit DGAT1, and thus can be useful as medicines for effectively treating dangerous diseases such as obesity, type 2 diabetes, abnormal lipidemia, metabolic syndrome (syndrome X) and the like, which are caused by DGAT1, with no adverse side effects.

BENZIMIDAZOLE DERIVATIVES USEFUL AS TRP M8 RECEPTOR MODULATORS

The present invention is directed to benzimidazole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by TRP M8 (transient receptor potential M8 channel). More particularly, the compounds of the present invention are useful in the treatment of inflammatory pain, inflammatory hyperalgesia, inflammatory hypersensitivity condition, neuropathic pain, neuropathic cold allodynia, inflammatory somatic hyperalgesia, inflammatory visceral hyperalgesia, cardiovascular disease aggravated by cold, anxiety and depression.

SUBSTITUTED IMIDAZOLINE COMPOUNDS

Substituted imidazoline derivatives corresponding to Formula I: a method for producing them from substituted aldehyde compounds of Formula B: and the use of such imidazoline derivatives and aldehyde compounds to treat pain, depression, urinary incontinenc